TOP HAT
This study will determine if ondansetron, a drug already used in the NHS, can be used as a treatment for visual hallucinations in people with Parkinson’s Disease or Lewy Body Dementia.
Visual hallucinations can be a common and distressing feature of Parkinson’s Disease and can have a significant impact on quality of life.
The Trial of Ondansetron as a Parkinson’s HAllucinations Treatment or TOP HAT is being carried out by researchers at the Northern Care Alliance on behalf of a team at UCL (University College London).
Criteria
- Aged 18+
- Diagnosed with Parkinson’s Disease (on stable medication) or Lewy Body Dementia
- Experience visual hallucinations
Location
- Salford Royal Hospital or Fairfield General Infirmary
Involves
Taking part involves:
- Attending an initial screening appointment (online/telephone)
- Attending two clinic appointments, which will include a range of tests (eg blood and urine samples, liver function, blood pressure, electrocardiogram, and body measurements) as well as completing a short questionnaire. (approx. 1 hour each)
- Attending four online/telephone appointments to assess progress, side effects, symptoms etc
- Taking the study drug for 12 weeks *
* Participants will be randomly selected to receive either the study drug (ondansetron) or a placebo
Transport and lunch will be provided for clinic visits.
Recruiting until
- 14 July 2024
Trial ID
- 266504
Share this study